

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVARTIS GENE THERAPIES, INC. & NOVARTIS
PHARMACEUTICALS CORPORATION,
Petitioner

v.

GENZYME CORPORATION,
Patent Owner.

Case: IPR2023-00609
Patent No. 9,051,542

**PATENT OWNER GENZYME'S NOTICE OF FILING EXHIBIT:
TELECONFERENCE TRANSCRIPT OF JULY 11, 2023**

Pursuant to 37 CFR § 42.6(e)(4)(ii), Patent Owner herewith submits the following July 11, 2023 Teleconference Transcript for IPR2023-00609 as Exhibit 2016:

Exhibit No.	Description
2001	[Reserved]
2002	[Reserved]
2003	Declaration of Katherine A. Helm, J.D., Ph.D. In Support of Motion for Admission <i>Pro Hac Vice</i>
2004	Declaration of Martin Christopher Davies in Support of Patent Owner's Preliminary Response ("Davies")
2005	Martyn Christopher Davies, Curriculum Vitae
2006	Xie et al., " <i>Large-Scale Production, Purification and Crystallization of Wild-Type Adeno-Associated Virus-2</i> ," 122 J. Virol. Methods 17 (2004) ("Xie")
2007	J.F. Wright et al., " <i>Identification of Factors that Contribute to Recombinant AAV2 Particle Aggregation and Methods to Prevent Its Occurrence during Vector Purification and Formulation</i> ," 12 Molecular Therapy 171 (July 2005)
2008	A.E. Smith, " <i>Gene Therapy: Where Are We</i> ," 354 The Lancet SI1 (July 1999)
2009	J.O. Konz et al. " <i>Development of a Purification Process for Adenovirus: Controlling Virus Aggregation to Improve the Clearance of Host Cell DNA</i> ," 21 Biotechnol. Prog. 466 (2005) ("Konz")
2010	Stipulation and Order to Amend Case Schedule, <i>Genzyme Corp. et al. v. Novartis Gene Therapies et al.</i> , C.A. No. 21-1736-RGA, D.I. 151 (D. Del.)
2011	October 11, 2022 Defendants' First Amended Invalidity Contentions in <i>Genzyme Corp. et al. v. Novartis Gene Therapies et al.</i> , C.A. No. 21-1736-RGA (D. Del.)
2012	June 2023 Docket Navigator Time to Trial Statistics in Patent Cases in the United States District Court for the District of Delaware
2013	Federal Judicial Caseload Statistics 2022

Exhibit No.	Description
2014	Order Denying Plaintiffs' Motion for Leave to File the Second Amended Complaint, <i>Genzyme Corp. et al. v. Novartis Gene Therapies et al.</i> , C.A. No. 21-1736-RGA, D.I. 147 (D. Del.)
2015	Disclaimer in Patent Under 37 CFR 1.321(a) of claims 1 and 2 of U.S. Patent No. 9,051,542
2016	July 11, 2023 Teleconference Transcript for IPR2023-00608 and IPR2023-00609

Dated: July 12, 2023

Respectfully submitted,

By: /Blaine M. Hackman/
Blaine Hackman, Reg. No. 67,479
Dechert LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
Tel: 212-698-3500
Fax: 212-698-3599
Blaine.hackman@dechert.com

*Counsel for Patent Owner Genzyme,
Corporation*

CERTIFICATE OF SERVICE

I certify that today in:

*Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation v.
Genzyme Corporation, IPR2023-00609 (U.S. Patent 9,051,542)*

I caused to be served a copy of:

Notice of Filing Teleconference Transcript of July 11, 2023

upon:

Novartis Gene Therapies, Inc. & Novartis Pharmaceuticals Corporation, c/o
John D. Livingstone, john.livingstone@finnegan.com
Amanda K. Murphy, Amanda.murphy@finnegan.com
Yieyie Yang, yieyie.yang@finnegan.com
M. David Weingarten, m.david.weingarten@finnegan.com
Cora Holt, cora.holt@finnegan.com
Christopher Weber, christoper.weber@finnegan.com

via:

electronic service to the email addresses above.

Dated: July 12, 2023

By: /Blaine M. Hackman/
Blaine Hackman, Reg. No. 67,479
Dechert LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
Tel: 212-698-3500
Fax: 212-698-3599
Blaine.hackman@dechert.com